No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
224 |
4. Check minimum number of eventsNone |
224 |
5. Include endpointsNone |
224 |
6. Filter based on genotype QC (FinnGen only) |
217 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D33
- Name in latin
- Neoplasma benignum cerebri non specificatum
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Brain, unspecified
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm of brain and other parts of central nervous system
- Benign neoplasms
- Neoplasms
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2424 | 1453 | 938 |
| Only index persons | 1513 | 913 | 600 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.03 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 48.74 | 51.26 | 44.54 |
| Only index persons | 42.00 | 45.00 | 37.43 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 217 | 134 | 83 |
| Unadjusted period prevalence (%) | 0.04 | 0.05 | 0.04 |
| Median age at first event (years) | 42.21 | 41.21 | 43.82 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 224
- Matched controls
- 2240
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D33.2
ICD-10 Finland
Benign neoplasm: Brain, unspecified
+∞
123.7
107
*
22500
ICD-8 Finland
Benign neoplasm of brain and other parts of nervous system, Brain
+∞
75.4
68
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
12.2
66.6
82
101
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
14.2
60.5
63
60
2250A
ICD-9 Finland
Benign neoplasm of brain and other parts of nervous system, Brain
+∞
60.2
55
*
2152
FHL
Extraction, big brain
+∞
38.7
36
*
9530/0-C70.0
ICD-O-3
Meningioma, NOS, of cerebral meninges
58.6
33.8
39
8
N03AF02
ATC
oxcarbazepine; oral
12.4
33.0
35
33
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
42.5
31.8
39
11
D32.00
ICD-10 Finland
Benign tumor of the meninges on the outer surface of the cerebrum
41.1
28.4
35
10
N03AF01
ATC
carbamazepine; oral, rectal
7.3
25.6
42
69
D32.02
ICD-10 Finland
Benign tumor of the meninges at the base of the brain
36.7
23.1
29
9
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.6
21.5
47
102
G40.9
ICD-10 Finland
Epilepsy, unspecified
8.3
20.0
28
38
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
9.3
19.6
25
30
101
Kela drug reimbursment
Anterior pituitary hypofunction
206.6
18.8
19
*
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
27.9
18.7
25
10
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
72.8
18.0
20
*
E23.00
ICD-10 Finland
Panhypopituitarism
103.4
17.8
19
*
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
17.9
17.5
27
17
2252A
ICD-9 Finland
Benign neoplasm of brain and other parts of nervous system, Cerebral meninges
+∞
16.9
16
*
XCK00
NOMESCO Finland
Perimetry
5.5
16.5
35
73
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
16.4
15.8
25
17
D33.30
ICD-10 Finland
Acoustic neuroma
48.7
15.3
18
*
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
12.6
14.2
25
22
N03AX14
ATC
levetiracetam; systemic
12.1
13.9
25
23
D33.00
ICD-10 Finland
Medial pilosytic astrocytoma of the cerebrum
148.6
13.6
14
*
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
20.6
13.2
19
10
N03AB02
ATC
phenytoin; systemic
13.5
12.4
21
17
H53.4
ICD-10 Finland
Visual field defects
14.5
12.2
20
15
H02AB09
ATC
hydrocortisone; systemic
12.1
11.8
21
19
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
21.4
11.3
16
8
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
63.1
10.7
12
*
22520
ICD-8 Finland
Benign neoplasm of brain and other parts of nervous system, Cerebral meninges
115.2
10.5
11
*
23810
ICD-8 Finland
Neoplasm of unspecified nature of eye, brain and other parts of nervous system, Brain
115.2
10.5
11
*
G93.0
ICD-10 Finland
Cerebral cysts
115.2
10.5
11
*
9380/3-C71.9
ICD-O-3
Glioma, malignant of brain, NOS
115.2
10.5
11
*
XA800
NOMESCO Finland
Neuropsychological investigation
5.3
10.0
21
43
D32.0
ICD-10 Finland
Benign neoplasm: Cerebral meninges
57.6
9.7
11
*
AA1AD
NOMESCO Finland
CT of head and brain
2.6
9.6
78
386
N05BA09
ATC
clobazam; oral
31.5
9.5
12
*
D43.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, supratentorial
104.3
9.5
10
*
2151
FHL
Resection, big brain
104.3
9.5
10
*
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.4
8.4
33
109
D33.05
ICD-10 Finland
Other lateral benign tumor in temporal lobe
+∞
8.4
8
*
D32.9
ICD-10 Finland
Benign neoplasm: Meninges, unspecified
34.7
8.1
10
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.3
8.1
33
112
H47.2
ICD-10 Finland
Optic atrophy
46.6
7.8
9
*
D33.02
ICD-10 Finland
Another benign medial tumor of the cerebrum
82.7
7.5
8
*
AAG50
NOMESCO Finland
Stereotactic intracranial radiotherapy
82.7
7.5
8
*
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
82.7
7.5
8
*
D32.06
ICD-10 Finland
Benign tumor of the meninges os petrosum or clivus area
+∞
7.3
7
*
H01AC01
ATC
somatropin; parenteral
+∞
7.3
7
*
9161/1-C71.6
ICD-O-3
Hemangioblastoma of cerebellum, NOS
+∞
7.3
7
*
N03AG01
ATC
valproic acid; systemic, rectal
3.8
7.2
23
66
78020
ICD-8 Finland
Certain symptoms referable to nervous system and special senses, Convulsions
20.8
7.2
10
5
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.5
7.1
53
249
G40.2
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
14.4
7.0
11
8
H02AB02
ATC
dexamethasone; systemic
2.8
7.0
37
146
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.9
6.9
35
134
CS5Z4
NOMESCO Finland
Specialised imaging for glaucoma
11.4
6.9
12
11
Z01.1
ICD-10 Finland
Examination of ears and hearing
2.6
6.9
43
185
102
Kela drug reimbursment
Diabetes insipidus
41.3
6.8
8
*
D33.39
ICD-10 Finland
Benign tumor of the cranial nerves UNS
71.8
6.5
7
*
G40.19
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
14.9
6.5
10
7
D32.01
ICD-10 Finland
Benign tumor of meninges on interhemispheric surface
18.7
6.3
9
5
E22.1
ICD-10 Finland
Hyperprolactinaemia
+∞
6.3
6
*
D33.08
ICD-10 Finland
Another benign tumor of the cerebral ventricle
+∞
6.3
6
*
WF099
NOMESCO Finland
Other radiotherapy
27.5
6.3
8
*
H03AA01
ATC
levothyroxine sodium; systemic
2.2
6.0
63
340
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
11
13
8.83
5.62
1.5
1.4
—
—
—
0
0
117
835
1.84
4.79
6.9
6.9
1.22
1.22
mmol/l
0.02
105
711
135
1035
1.77
4.10
5.2
5.0
6.50
6.64
mmol/l
0.31
130
957
106
770
1.71
3.82
6.1
5.9
1.21
1.22
mmol/l
0.15
101
702
35
187
2.03
3.34
8.5
9.3
2.04
1.16
mmol/l
0.96
28
155
6
9
6.81
2.88
1.0
1.6
—
—
—
0
0
22
107
2.17
2.68
4.9
7.5
1.27
1.52
%
0.65
22
107
18
81
2.33
2.62
5.2
9.0
25.04
24.54
mmol/l
0.42
18
81
8
22
3.73
2.38
1.1
1.2
—
—
—
0
0
7
17
4.21
2.38
1.0
1.1
154.43
325.06
pmol/l
—
7
17
21
106
2.08
2.34
5.1
7.8
0.65
0.70
%
0.20
21
106
8
23
3.57
2.29
1.1
1.2
—
—
—
0
0
20
100
2.10
2.29
4.9
4.7
24.09
24.44
mmol/l
0.20
20
100
7
18
3.98
2.27
1.1
1.1
—
—
—
0
0
8
24
3.42
2.20
1.6
1.5
0.17
0.43
nmol/l
—
8
18
6
14
4.37
2.16
1.3
1.4
2.32
1.90
mmol/l
—
6
14
7
20
3.58
2.07
1.1
1.2
—
—
—
0
0
100
799
1.45
2.01
2.4
2.6
—
—
—
0
0
48
330
1.58
1.97
1.8
1.7
1416.79
1236.58
nmol/l
0.54
39
254
31
190
1.73
1.97
1.7
1.8
—
—
—
0
0
9
33
2.80
1.95
1.4
1.5
—
—
—
0
0
24
137
1.84
1.92
2.3
2.5
65.00
63.50
ml/min/173m2
—
10
58
99
797
1.43
1.89
10.4
13.1
1.22
1.26
inr
0.13
25
238
41
275
1.60
1.87
1.7
1.9
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
12
4.23
1.83
1.4
1.3
—
—
—
0
0
21
117
1.88
1.81
3.7
3.4
79.00
74.10
ng/l
0.19
21
106
8
180
0.42
1.78
1.9
1.7
—
—
—
0
0
154
1353
1.44
1.75
5.4
4.0
14.85
14.74
pmol/l
0.19
142
1225
31
198
1.66
1.71
4.7
6.5
102.68
104.17
mmol/l
0.65
31
198
10
201
0.47
1.53
1.9
1.9
—
—
—
0
0
55
412
1.44
1.50
2.1
2.3
—
—
—
0
0
87
712
1.36
1.42
3.0
2.2
78.25
76.50
nmol/l
0.22
82
630
53
399
1.43
1.41
5.5
4.2
1.02
1.02
kg/l
0.04
13
49
194
1809
1.54
1.39
20.0
15.9
139.34
139.70
mmol/l
0.96
189
1759
29
194
1.57
1.35
1.7
1.9
—
—
—
0
0
194
1820
1.49
1.23
19.7
15.9
3.96
3.97
mmol/l
0.17
189
1768
53
409
1.39
1.23
1.8
2.0
3.22
3.18
mg/l
0.04
43
369
190
1779
1.45
1.18
16.6
13.9
25.68
21.59
mg/l
0.78
157
1385
8
40
2.04
1.13
2.6
2.2
23.55
24.44
mmol/l
—
8
40
10
51
2.01
1.13
1.0
1.1
—
—
—
0
0
5
21
2.41
1.09
1.6
1.4
—
—
—
0
0
9
47
1.95
1.03
1.2
1.3
—
—
—
0
0
29
207
1.46
1.03
5.1
4.5
34.67
32.33
%
0.52
24
138
5
23
2.20
0.98
1.2
1.0
—
—
—
0
0
67
554
1.30
0.98
3.4
2.4
56.46
54.65
u/l
0.19
61
514
16
101
1.63
0.96
2.4
3.7
0.93
1.29
mmol/l
—
6
78
6
27
2.25
0.94
1.0
1.1
6.30
7.95
mmol/l
—
6
22
47
372
1.33
0.93
1.7
1.8
453.44
470.88
pmol/l
0.19
36
312
10
56
1.82
0.89
4.4
3.0
3.65
3.93
mmol/l
—
10
56
82
705
1.26
0.87
3.6
3.9
20.30
39.48
ng/l
1.87
61
488
59
487
1.29
0.87
5.7
4.2
0.00
0.00
estimate
-0.00
12
178
37
470
0.75
0.87
1.9
2.7
325.16
6201.49
umol/l
1.95
31
408
26
197
1.36
0.70
4.4
6.2
1.03
1.04
mmol/l
0.09
26
177
14
94
1.52
0.68
1.9
1.5
—
—
—
0
0
34
270
1.31
0.67
3.0
4.1
0.83
0.81
mmol/l
0.80
34
251
5
29
1.74
0.64
1.0
1.4
—
—
—
0
0
8
50
1.62
0.62
1.6
2.6
—
—
—
0
0
11
162
0.66
0.61
1.3
1.8
—
—
—
0
0
8
55
1.47
0.56
1.3
1.4
—
—
—
0
0
26
206
1.30
0.54
11.4
8.1
—
—
—
0
0
10
66
1.54
0.53
1.2
2.2
1.62
1.57
g/l
—
10
55
112
1035
1.16
0.51
9.2
9.4
4.38
4.05
e9/l
0.75
98
904
57
500
1.19
0.49
2.6
3.4
1093.34
1386.09
ng/l
0.42
50
422
7
49
1.44
0.46
1.0
1.1
—
—
—
0
0
5
32
1.57
0.42
2.6
2.2
—
—
—
0
0
27
323
0.81
0.41
1.3
1.3
74.11
31.30
iu/ml
—
10
115
8
59
1.37
0.41
2.8
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
174
1676
1.17
0.41
14.2
12.7
84.46
82.05
ml/min/173m2
0.76
146
1367
5
34
1.48
0.40
1.2
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
78
713
1.14
0.40
5.1
3.9
—
—
—
0
0
96
890
1.14
0.40
4.9
3.8
0.00
0.01
estimate
0.50
14
188
5
35
1.44
0.39
1.0
1.6
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
9
70
1.30
0.37
1.4
1.9
—
—
—
0
0
27
318
0.83
0.36
1.4
1.3
16.37
10.86
u/ml
0.20
12
134
6
42
1.44
0.36
1.5
1.3
—
—
—
0
0
70
642
1.13
0.34
3.5
2.9
—
—
—
0
0
167
1613
1.14
0.33
5.5
5.6
39.41
39.83
mmol/mol
0.25
156
1513
95
891
1.11
0.31
6.1
5.1
0.00
0.00
estimate
-0.00
14
180
33
289
1.17
0.30
3.1
2.4
0.34
1.00
e6/l
2.79
16
164
96
903
1.11
0.30
4.9
3.9
0.00
0.00
estimate
-0.00
14
173
127
1324
0.91
0.28
4.9
4.1
11.87
11.37
mm/h
0.17
121
1219
8
65
1.24
0.27
5.0
1.6
4.47
5.15
ug/l
—
8
58
5
72
0.69
0.26
3.2
1.7
—
—
—
0
0
5
75
0.66
0.26
2.4
2.0
4.99
3.79
mg/l
—
5
60
14
170
0.81
0.26
2.4
3.6
—
—
—
0
0
16
134
1.21
0.23
3.0
2.4
—
10.23
—
0
6
5
39
1.29
0.23
1.0
1.3
—
—
—
0
0
5
41
1.22
0.22
1.2
2.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
25.77
—
0
11
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
119.71
—
0
12
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
200
1969
1.15
0.21
24.7
20.3
255.77
250.92
e9/l
0.51
195
1919
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
200
1970
1.14
0.20
24.7
20.3
4.44
4.49
e12/l
0.71
194
1909
200
1970
1.14
0.20
24.5
20.4
39.92
40.23
%
0.37
185
1871
0
14
0.00
0.20
0.0
1.3
—
190.69
—
0
14
0
14
0.00
0.20
0.0
1.7
—
17.00
—
0
14
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
6
49
1.23
0.20
1.5
2.0
—
—
—
0
0
14
118
1.20
0.19
1.9
1.5
—
—
—
0
0
167
1634
1.09
0.18
5.8
4.8
1.60
1.87
mu/l
2.90
152
1484
7
62
1.13
0.17
1.9
1.9
—
—
—
0
0
81
774
1.07
0.17
2.7
2.6
127.46
99.44
ug/l
0.88
73
718
8
68
1.18
0.17
1.5
1.8
—
—
—
0
0
141
1374
1.07
0.16
8.0
7.3
77.05
76.45
u/l
0.06
135
1291
10
83
1.21
0.15
2.9
2.3
1.49
1.24
%
—
10
83
36
333
1.10
0.15
3.0
3.9
16.99
250.54
ng/l
1.69
29
254
7
86
0.81
0.15
1.3
1.8
—
—
—
0
0
8
100
0.79
0.14
1.4
1.9
—
—
—
0
0
191
1885
1.09
0.13
11.7
10.2
26.15
25.86
u/l
0.08
183
1826
171
1737
0.93
0.13
4.7
4.4
1.48
1.49
mmol/l
0.10
164
1611
42
396
1.07
0.12
1.7
1.8
1.27
1.10
mg/l
0.13
26
310
118
1209
0.95
0.12
5.2
3.1
58.50
44.73
u/l
1.11
112
1133
172
1744
0.94
0.11
4.7
4.5
4.70
4.66
mmol/l
0.18
162
1626
5
45
1.11
0.10
1.0
1.3
—
—
—
0
0
5
46
1.09
0.09
1.0
1.7
—
—
—
0
0
48
459
1.06
0.09
1.7
1.7
1.88
1.42
mmol/l
1.77
43
384
29
272
1.08
0.09
3.2
2.7
1.89
3.37
e6/l
0.51
12
148
166
1682
0.95
0.09
4.3
4.0
1.32
1.27
mmol/l
0.56
159
1552
5
48
1.04
0.09
1.0
1.7
—
—
—
0
0
176
1780
0.95
0.09
5.0
4.9
2.77
2.76
mmol/l
0.09
163
1649
71
688
1.05
0.09
2.3
1.9
95.94
98.31
pmol/l
0.17
43
352
13
117
1.12
0.08
2.7
3.5
71.54
206.48
ng/l
2.75
13
105
41
428
0.95
0.08
1.3
1.3
1.35
1.47
u/ml
0.06
15
120
31
297
1.05
0.05
1.7
1.5
—
—
—
0
0
171
1698
1.03
0.03
4.7
4.5
5.69
5.94
mmol/l
2.11
161
1560
38
370
1.03
0.03
4.5
4.0
22.15
20.95
%
0.22
20
172
11
102
1.08
0.03
1.1
1.3
—
—
—
0
0
35
343
1.02
0.01
1.2
1.5
—
—
—
0
0
114
1147
0.99
0.01
2.6
3.2
—
—
—
0
0
51
504
1.02
0.00
3.8
2.7
0.36
0.32
e6/l
0.08
40
370
10
103
0.97
0.00
1.0
1.0
—
—
—
0
0
28
283
0.99
0.00
3.4
2.8
0.73
0.78
ug/l
0.14
22
172
50
495
1.01
0.00
3.3
3.7
4.08
6.22
mg/mmol
0.49
31
314
20
205
0.97
0.00
2.8
3.2
5.07
7.96
umol/l
0.81
15
182
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
5
57
0.87
0.00
1.2
1.1
—
—
—
0
0
5
52
0.96
-0.00
2.0
1.6
—
0.11
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
1585.29
—
0
7
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
-0.00
0.0
2.8
—
93.83
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
5
0.00
-0.00
0.0
1.0
—
152.40
—
0
5
0
7
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
17.54
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
9
97
0.92
-0.00
1.2
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
9.71
—
0
8
6
60
1.00
-0.00
1.5
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
4.9
—
98.43
—
0
7
0
8
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
5
58
0.86
-0.00
1.2
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_BRAIN_NOS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_BRAIN_NOS | 1.973 [1.46, 2.67] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.021 |
During the follow-up period (1.1.1998 — 31.12.2019), 87 out of 375 females with CD2_BENIGN_BRAIN_NOS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_BRAIN_NOS | 1.925 [1.33, 2.79] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.015 |
During the follow-up period (1.1.1998 — 31.12.2019), 59 out of 249 males with CD2_BENIGN_BRAIN_NOS died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_BRAIN_NOS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.144% | 0.407% |
| 5 | 1.001% | 2.468% |
| 10 | 2.701% | 5.618% |
| 15 | 4.635% | 10.786% |
| 20 | 7.798% | 17.817% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_BRAIN_NOS – Benign neoplasm: Brain, unspecified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data